HC Wainwright Reiterates Neutral Rating for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ:DRRXGet Free Report)‘s stock had its “neutral” rating reiterated by HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports.

A number of other research analysts have also commented on the stock. Oppenheimer restated an “outperform” rating and set a $5.00 price target on shares of DURECT in a research report on Monday, April 1st. StockNews.com raised shares of DURECT from a “sell” rating to a “hold” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

View Our Latest Research Report on DRRX

DURECT Stock Performance

Shares of NASDAQ:DRRX opened at $1.26 on Wednesday. The company has a market capitalization of $39.11 million, a P/E ratio of -1.33 and a beta of 0.94. DURECT has a fifty-two week low of $0.47 and a fifty-two week high of $6.74. The company’s 50-day moving average is $1.04 and its 200 day moving average is $0.87.

DURECT (NASDAQ:DRRXGet Free Report) last released its quarterly earnings data on Wednesday, March 27th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.09. DURECT had a negative net margin of 279.77% and a negative return on equity of 328.25%. The business had revenue of $2.67 million for the quarter, compared to the consensus estimate of $2.70 million. As a group, research analysts predict that DURECT will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Richmond Brothers Inc. raised its stake in shares of DURECT by 48.2% during the 1st quarter. Richmond Brothers Inc. now owns 768,344 shares of the specialty pharmaceutical company’s stock worth $930,000 after acquiring an additional 250,050 shares in the last quarter. CM Management LLC raised its stake in DURECT by 11.7% in the 3rd quarter. CM Management LLC now owns 525,000 shares of the specialty pharmaceutical company’s stock worth $1,307,000 after acquiring an additional 55,000 shares during the last quarter. Gagnon Securities LLC boosted its position in DURECT by 6.0% in the first quarter. Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock valued at $460,000 after buying an additional 21,425 shares during the last quarter. Tocqueville Asset Management L.P. boosted its holdings in shares of DURECT by 10.8% in the 1st quarter. Tocqueville Asset Management L.P. now owns 256,220 shares of the specialty pharmaceutical company’s stock valued at $310,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Ironwood Investment Management LLC grew its position in DURECT by 144.6% during the 3rd quarter. Ironwood Investment Management LLC now owns 206,267 shares of the specialty pharmaceutical company’s stock worth $514,000 after purchasing an additional 121,930 shares during the period. Institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

(Get Free Report)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Featured Stories

Analyst Recommendations for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.